Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma. The company also develops MT-4019, a preclinical drug candidate targeting CD38; and other candidates that are in pre-clinical development for the treatment of solid and hematological cancers. Molecular Templates, Inc. is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MTEM
CUSIP88580720
Phone512-869-1555
Debt
Debt-to-Equity Ratio0.04
Current Ratio4.54
Quick Ratio4.54
Price-To-Earnings
Trailing P/E Ratio-2.69
Forward P/E Ratio-4.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.39 million
Price / Sales45.26
Cash FlowN/A
Price / CashN/A
Book Value$2.87 per share
Price / Book1.98
Profitability
EPS (Most Recent Fiscal Year)($2.11)
Net Income$-23,140,000.00
Net Margins-514.16%
Return on Equity-40.24%
Return on Assets-33.82%
Miscellaneous
Employees38
Outstanding Shares27,060,000
Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions
What is Molecular Templates' stock symbol?
Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."
When did Molecular Templates' stock split? How did Molecular Templates' stock split work?
Molecular Templates's stock reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.
How were Molecular Templates' earnings last quarter?
Molecular Templates Inc (NASDAQ:MTEM) released its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.07. The biotechnology company had revenue of $0.48 million for the quarter. Molecular Templates had a negative net margin of 514.16% and a negative return on equity of 40.24%. View Molecular Templates' Earnings History.
When is Molecular Templates' next earnings date?
What price target have analysts set for MTEM?
2 brokerages have issued 1-year price objectives for Molecular Templates' shares. Their forecasts range from $0.40 to $10.00. On average, they anticipate Molecular Templates' stock price to reach $5.20 in the next twelve months. View Analyst Ratings for Molecular Templates.
Who are some of Molecular Templates' key competitors?
Some companies that are related to Molecular Templates include ChemoCentryx (CCXI), Achaogen (AKAO), Cara Therapeutics (CARA), Obseva (OBSV), Viking Therapeutics (VKTX), TIGENIX/S (TIG), Lannett (LCI), AC Immune (ACIU), Rigel Pharmaceuticals (RIGL), Stemline Therapeutics (STML), Zymeworks (ZYME), Merus (MRUS), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP) and ZIOPHARM Oncology (ZIOP).
Who are Molecular Templates' key executives?
Molecular Templates' management team includes the folowing people:
- Dr. Eric E. Poma Ph.D., CEO, Chief Scientific Officer & Director (Age 46)
- Ms. Jason S Kim, Pres & COO (Age 43)
- Mr. Adam D. Cutler B.A., Chief Financial Officer
- Dr. Barbara A. Ruskin Ph.D., J.D., Sr. VP, Gen. Counsel & Chief Patent Officer
- Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 51)
Has Molecular Templates been receiving favorable news coverage?
News headlines about MTEM stock have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Molecular Templates earned a daily sentiment score of 0.13 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.42 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Molecular Templates' major shareholders?
Molecular Templates' stock is owned by many different of institutional and retail investors. Top institutional investors include Caxton Corp (3.84%), BVF Inc. IL (2.54%), First Eagle Investment Management LLC (2.28%), Lyon Street Capital LLC (1.14%), Millennium Management LLC (1.09%) and JPMorgan Chase & Co. (0.18%). View Institutional Ownership Trends for Molecular Templates.
Which institutional investors are selling Molecular Templates stock?
Which institutional investors are buying Molecular Templates stock?
MTEM stock was purchased by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Millennium Management LLC, Dimensional Fund Advisors LP, Caxton Corp, JPMorgan Chase & Co., Alps Advisors Inc. and Northern Trust Corp. View Insider Buying and Selling for Molecular Templates.
How do I buy shares of Molecular Templates?
Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Molecular Templates' stock price today?
One share of MTEM stock can currently be purchased for approximately $5.67.
How big of a company is Molecular Templates?
Molecular Templates has a market capitalization of $146.94 million and generates $3.39 million in revenue each year. The biotechnology company earns $-23,140,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Molecular Templates employs 38 workers across the globe.
How can I contact Molecular Templates?
Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]
MarketBeat Community Rating for Molecular Templates (MTEM)
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
